

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6855)

VOLUNTARY ANNOUNCEMENT

PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME

This announcement is made by Ascentage Pharma Group International (the “**Company**”) on a voluntary basis. Reference is made to the announcements of the Company dated June 23, 2022 and July 14, 2022 (the “**Announcements**”) in relation to, among other things, the adoption of the 2022 RSU Scheme and the initial grant of the 2022 Awards thereunder. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

During the period from July 12, 2022 to July 15, 2022, the Trustee purchased a total of 1,635,000 existing Shares (the “**First Batch of Purchased Shares**”) on-market for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon exercise. Details of the First Batch of Purchased Shares are as follows:

Purchase period	:	July 12, 2022 to July 15, 2022
Total number of the First Batch of Purchased Shares	:	1,635,000 Shares
Percentage of the First Batch of Purchased Shares to the total number of issued Shares as at the date of this announcement	:	Approximately 0.618%
Total consideration paid for the First Batch of Purchased Shares (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	HK\$29,877,940.00
Average consideration per First Batch of Purchased Share (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	Approximately HK\$18.27

Further and on October 21, 2022, the Trustee purchased a total of 10,000 existing Shares (the “**Second Batch of Purchased Shares**”, and together with the First Batch of Purchased Shares, the “**Purchased Shares**”) on-market for the purpose of the 2022 RSU Scheme to satisfy the RSUs upon exercise. Details of the Second Batch of Purchased Shares and the latest information about the Shares held by the Trustee under the Scheme are as follows:

Purchase date	:	October 21, 2022
Total number of the Second Batch of Purchased Shares	:	10,000 Shares
Percentage of the Second Batch of Purchased Shares to the total number of issued Shares as at the date of this announcement	:	Approximately 0.004%
Total consideration paid for the Second Batch of Purchased Shares (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	HK\$157,200.00
Average consideration per Second Batch of Purchased Share (excluding all related expenses, transaction levy, brokerage, tax, duties and levies)	:	Approximately HK\$15.72
Total number of Shares held by the Trustee for the purpose of the 2022 RSU Scheme immediately after the aforesaid purchases	:	1,645,000 Shares

The Purchased Shares are currently held by the Trustee in accordance with the 2022 RSU Scheme Rules and the terms of the trust deed entered into between the Company and the Trustee. As at the date of this announcement, no further grant of Awards has been made pursuant to the 2022 RSU Scheme apart from the initial grant of the 2022 Awards as disclosed in the Announcements.

By Order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, People’s Republic of China, October 21, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.